异基因外周血造血干细胞移植并巨细胞病毒感染的分析

目的探讨异基因外周血造血干细胞移植(PBSCT)中对巨细胞病毒(CMV)感染的监测及早期干预性治疗的可行性。方法对2005年1月~2006年12月在上海交通大学附属第一人民医院接受异基因PBSCT的35例患者进行回顾分析,分析CMV病的发生率及其相关的危险因素。结果35例患者中22例发生CMV血症,6例出现CMV病。其中2例发生CMV间质性肺炎(CMV-IP),均治疗无效死亡。通过CMV-DNA检测,对结果阳性而无临床症状者进行干预性治疗使CMV-DNA转阴,同时减少可能导致CMV病发生的高危因素,则可降低CMV病发生率。结论CMV病是异基因PBSCT的常见并发症,也是主要致死原因之一。本组所采用的方法可减少CMV病的发生率及CMV病的病死率。

Clinical study of cytomegalovirus infection in allogeneic peripheral blood stem cell transplantation

Objective To explore feasibility of pre-emptive therapy of cytomegalovirus(CMV) infection in allogeneic peripheral blood stem cell transplantation. Methods Thirty-five allogeneic PBSCT patients in First People's Hospital affiliated to Shanghai Jiaotong University. Performed between January 2005 and December 2006, were analyzed retrospectively .To study the morbidity and risk factors of CMV diseases. Results In 35 patients, 22 cases had CMV-DNA positively, 6 cases had CMV diseases, 2 of them with CMV interstitial pneumonia (CMV-IP).died. Patient with positive plasma CMV-DNA received pre-emptive therapy till their plasma CMV-DNA turned negative. Conclusion Plasma CMV-DNA monitoring and pre-emptive therapy could reduce the morbidity and mortality of CMV diseases, in allogeneic PBSCT patients.